ARMO BioSciences was a clinical-stage immuno-oncology biopharmaceutical company based in Redwood City, California, developing biologic therapeutics that activate a patient's own immune system to fight cancer. Its lead candidate was pegilodecakin (AM0010), a PEGylated recombinant human interleukin-10 (IL-10) evaluated across solid tumors. - View it on GitHub